Unichem Laboratories Ltd Stock Falls to 52-Week Low of Rs.345.2

Stock Performance and Market Context

On the day the new low was recorded, Unichem Laboratories Ltd’s share price fell by 3.31% intraday, closing with a day change of -1.69%. This performance lagged the Pharmaceuticals & Biotechnology sector by 1.94%, signalling relative weakness within its industry group. The stock is currently trading below all major moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained downward momentum.

In contrast, the broader market index, Sensex, experienced a volatile session. After opening 142.71 points higher, it reversed to close down by 289.74 points at 82,129.04, a decline of 0.18%. The Sensex remains 4.91% below its 52-week high of 86,159.02, with its 50-day moving average positioned above the 200-day moving average, suggesting a cautiously positive medium-term trend for the benchmark.

Long-Term and Recent Price Trends

Over the past year, Unichem Laboratories Ltd’s stock has delivered a negative return of 45.33%, a stark contrast to the Sensex’s positive 10.01% gain over the same period. The stock’s 52-week high was Rs.727.95, underscoring the extent of the decline to the current low of Rs.345.2. This prolonged downtrend has also resulted in underperformance relative to the BSE500 index across multiple time frames, including the last three years, one year, and three months.

Financial Metrics and Profitability Concerns

Unichem Laboratories Ltd’s financial profile reveals several areas of concern. The company’s Debt to EBITDA ratio stands at a high 4.87 times, indicating a relatively low capacity to service its debt obligations. This elevated leverage level has been a factor in the company’s current rating, which was downgraded from Strong Sell to Sell on 16 Feb 2026, with a Mojo Score of 31.0 reflecting this cautious stance.

Profitability metrics also highlight challenges. The average Return on Equity (ROE) is a modest 1.44%, signalling limited profitability generated per unit of shareholders’ funds. Recent quarterly results for the period ending December 2025 further illustrate this trend, with Profit Before Tax (PBT) excluding other income falling by 77.2% to Rs.6.11 crores compared to the previous four-quarter average. Net Profit After Tax (PAT) declined by 56.0% to Rs.16.13 crores over the same comparison period.

Interest expenses have increased notably, with the latest six-month figure rising by 30.50% to Rs.15.66 crores, adding pressure on the company’s earnings and cash flow.

Growth and Valuation Factors

Despite the subdued profitability and leverage concerns, Unichem Laboratories Ltd has demonstrated healthy long-term growth in operating profit, which has expanded at an annual rate of 148.09%. This robust growth in operating earnings contrasts with the more modest net sales growth of 11.95% per annum over the last five years.

The company’s Return on Capital Employed (ROCE) is recorded at 4.9%, and it maintains an enterprise value to capital employed ratio of 1, suggesting a valuation that some may consider attractive relative to its capital base. Additionally, the stock trades at a discount compared to its peers’ average historical valuations, with a Price/Earnings to Growth (PEG) ratio of 0.8, reflecting the relationship between its price, earnings growth, and valuation.

Shareholding and Sector Position

The majority ownership of Unichem Laboratories Ltd remains with its promoters, maintaining a stable shareholding structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance amid broader market volatility. While the sector has seen some resilience, Unichem’s stock has lagged behind, reflecting company-specific factors rather than sector-wide trends.

Overall, the stock’s recent decline to Rs.345.2 marks a significant technical and psychological level, representing the lowest price point in the past 52 weeks. This level is substantially below the stock’s peak of Rs.727.95, underscoring the challenges faced by the company in recent periods.

Summary of Key Financial and Market Indicators

To encapsulate, Unichem Laboratories Ltd’s current market and financial profile includes:

• New 52-week low price of Rs.345.2 recorded on 26 Feb 2026
• One-year stock return of -45.33%, underperforming Sensex’s 10.01% gain
• Debt to EBITDA ratio of 4.87 times, indicating elevated leverage
• Decline in quarterly PBT and PAT by 77.2% and 56.0% respectively versus prior four-quarter averages
• Interest expense growth of 30.50% over the latest six months
• Operating profit growth at an annual rate of 148.09% over the long term
• ROE averaging 1.44%, ROCE at 4.9%, and a PEG ratio of 0.8
• Stock trading below all major moving averages, signalling sustained downward momentum

These factors collectively illustrate the current state of the company’s stock and financial health as it navigates a challenging market environment.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today